OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schuster Dicsusses CAR T-Cell Therapy in DLBCL

March 1st 2018

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Richter on Toxicities of Treatments for Multiple Myeloma

February 28th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Dr. Singh Discusses Challenges for GIST

February 28th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses challenges for patients with gastrointestinal stromal tumors (GIST).

Dr. O'Malley on the Tolerability of PARP Inhibitors in Ovarian Cancer

February 28th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.

Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer

February 28th 2018

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Castle on Adjuvant Versus Early Salvage Therapy in Prostate Cancer

February 28th 2018

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Dr. Younes Discusses Ibrutinib Plus Nivolumab in NHL

February 27th 2018

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

Dr. He on the Future of Precision Medicine in GI Malignancies

February 27th 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

Dr. Morse Reflects on Recent Data in Advanced CRC

February 27th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.

Dr. DeAngelo Discusses Ongoing Trials in AML

February 27th 2018

Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

Dr. Gomella on Enzalutamide in Prostate Cancer

February 27th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Dr. Mutch on Biomarkers in Endometrial Cancer

February 27th 2018

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC

February 27th 2018

Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).

Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC

February 27th 2018

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).

Dr. Finn on the FDA Approval of Frontline Abemaciclib in HR+/HER2- Breast Cancer

February 27th 2018

Richard S. Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, discusses the FDA approval of abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

Dr. Borghaei Discusses the PACIFIC Trial in Lung Cancer

February 27th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).

Dr. Plimack on Immunotherapy Combinations in Bladder Cancer

February 27th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy combinations for patients with bladder cancer.

Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC

February 27th 2018

Suresh A. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses data with pembrolizumab (Keytruda) and chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Hill Discusses Combinations in MCL

February 26th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma.

Dr. Klopp Discusses Chemoradiation in Endometrial Cancer

February 26th 2018

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.